Market Overview:
The global hospital acquired infections (HAI) diagnostics market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth is attributed to the increasing incidence of HAIs, growing demand for rapid and accurate diagnosis, and rising awareness about HAIs. The molecular diagnostics tests segment is expected to grow at the highest CAGR during the forecast period. This can be attributed to the increasing demand for molecular diagnostics tests due to their accuracy and speed in detecting pathogens. The bloodstream infections (BSI) segment accounted for the largest share of the global hospital acquired infections (HAI) diagnostics market in 2017.
 Diagnostics Industry Outlook.svg)
Product Definition:
Hospital acquired infections (HAI) diagnostics is the identification of the organisms that cause infection in hospitalized patients. This information is used to develop targeted prevention strategies and improve patient outcomes.
Molecular Diagnostics Tests:
Molecular diagnostics tests are used to detect and identify infectious microorganisms such as bacteria, viruses, fungi or parasites. These tests are widely applied in the detection of hospital-acquired infections (HAIs) which is a major factor driving market growth. According to CDC estimates, about 1 in 25 hospital patients has at least one healthcare-associated infection per day which leads to an estimated 5% of mortality every year.
Other In-vitro Diagnostic Tests:
Other in-vitro diagnostic tests include immunoassays, monoclonal and polyclonal antibodies, flow cytometry, latex slide agglutination test (LLAT), enzymeimmunoassays (EIA), radioimmunoassay and western blotting. Other tests are used for the diagnosis of infection but are not specific for a particular infectious agent.
Application Insights:
The bloodstream infections segment dominated the overall market in terms of revenue as well as volume in 2017. This is owing to a rise in the prevalence of chronic diseases, especially cardiovascular and kidney diseases, that require frequent hospital admissions. Furthermore, an increase in the number of surgeries has led to an increased risk of developing bloodborne infections. According to a study published by NCBI, around 1% - 10% patients develop a blood infection during every surgery and this risk increases with longer duration of procedures along with age. Thus, increasing incidences across the globe are contributing towards segment growth at a lucrative rate.
Urine tract infections (UTI) segment is expected to grow at fastest rate during forecast period due largely preventative measures taken by healthcare providers such as catheters use for bladder irrigation.
Regional Analysis:
North America dominated the global hospital acquired infections diagnostics market in 2016. This can be attributed to the presence of well-established healthcare facilities, increasing prevalence of target diseases, and rising government initiatives & funding for research activities. For instance, in 2015, the U.S.
Asia Pacific region is anticipated to witness lucrative growth during the forecast period owing to improving healthcare infrastructure.
Growth Factors:
- Increasing incidence of hospital acquired infections (HAI) is expected to drive the demand for HAI diagnostics over the forecast period.
- Rising awareness about the prevention and diagnosis of HAIs is anticipated to boost the market growth.
- Technological advancements in HAI diagnostics are projected to offer lucrative opportunities for market players in this domain over the forecast period.
- Growing number of mergers and acquisitions among key players is likely to propel the growth of this market during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Hospital Acquired Infections (HAI) Diagnostics Market Research Report
By Type
Molecular Diagnostics Tests, Other In-vitro Diagnostic Tests
By Application
Bloodstream Infections (BSI), Urinary Tract Infections (UTI), Surgical Site Infections (SSI), Pneumonia, Others
By Companies
BioMérieux, Abbott Laboratories, Roche AG, Siemens Healthcare
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
162
Number of Tables & Figures
114
Customization Available
Yes, the report can be customized as per your need.
Global Hospital Acquired Infections (HAI) Diagnostics Market Report Segments:
The global Hospital Acquired Infections (HAI) Diagnostics market is segmented on the basis of:
Types
Molecular Diagnostics Tests, Other In-vitro Diagnostic Tests
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Bloodstream Infections (BSI), Urinary Tract Infections (UTI), Surgical Site Infections (SSI), Pneumonia, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- BioMérieux
- Abbott Laboratories
- Roche AG
- Siemens Healthcare
 Diagnostics Market Overview.svg)
Highlights of The Hospital Acquired Infections (HAI) Diagnostics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Molecular Diagnostics Tests
- Other In-vitro Diagnostic Tests
- By Application:
- Bloodstream Infections (BSI)
- Urinary Tract Infections (UTI)
- Surgical Site Infections (SSI)
- Pneumonia
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hospital Acquired Infections (HAI) Diagnostics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Diagnostics Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
HAI is a term used to describe infections that are acquired in the hospital setting. HAI can be caused by a variety of bacteria, viruses, or fungi. Some of the most common HAI include pneumonia, urinary tract infection (UTI), and sepsis.
Some of the major players in the hospital acquired infections (hai) diagnostics market are BioM©rieux, Abbott Laboratories, Roche AG, Siemens Healthcare.
The hospital acquired infections (hai) diagnostics market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hospital Acquired Infections (HAI) Diagnostics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hospital Acquired Infections (HAI) Diagnostics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hospital Acquired Infections (HAI) Diagnostics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hospital Acquired Infections (HAI) Diagnostics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hospital Acquired Infections (HAI) Diagnostics Market Size & Forecast, 2018-2028
4.5.1 Hospital Acquired Infections (HAI) Diagnostics Market Size and Y-o-Y Growth
4.5.2 Hospital Acquired Infections (HAI) Diagnostics Market Absolute $ Opportunity
Chapter 5 Global Hospital Acquired Infections (HAI) Diagnostics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Hospital Acquired Infections (HAI) Diagnostics Market Size Forecast by Type
5.2.1 Molecular Diagnostics Tests
5.2.2 Other In-vitro Diagnostic Tests
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Hospital Acquired Infections (HAI) Diagnostics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Hospital Acquired Infections (HAI) Diagnostics Market Size Forecast by Applications
6.2.1 Bloodstream Infections (BSI)
6.2.2 Urinary Tract Infections (UTI)
6.2.3 Surgical Site Infections (SSI)
6.2.4 Pneumonia
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hospital Acquired Infections (HAI) Diagnostics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hospital Acquired Infections (HAI) Diagnostics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Hospital Acquired Infections (HAI) Diagnostics Analysis and Forecast
9.1 Introduction
9.2 North America Hospital Acquired Infections (HAI) Diagnostics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Hospital Acquired Infections (HAI) Diagnostics Market Size Forecast by Type
9.6.1 Molecular Diagnostics Tests
9.6.2 Other In-vitro Diagnostic Tests
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Hospital Acquired Infections (HAI) Diagnostics Market Size Forecast by Applications
9.10.1 Bloodstream Infections (BSI)
9.10.2 Urinary Tract Infections (UTI)
9.10.3 Surgical Site Infections (SSI)
9.10.4 Pneumonia
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Hospital Acquired Infections (HAI) Diagnostics Analysis and Forecast
10.1 Introduction
10.2 Europe Hospital Acquired Infections (HAI) Diagnostics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Hospital Acquired Infections (HAI) Diagnostics Market Size Forecast by Type
10.6.1 Molecular Diagnostics Tests
10.6.2 Other In-vitro Diagnostic Tests
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Hospital Acquired Infections (HAI) Diagnostics Market Size Forecast by Applications
10.10.1 Bloodstream Infections (BSI)
10.10.2 Urinary Tract Infections (UTI)
10.10.3 Surgical Site Infections (SSI)
10.10.4 Pneumonia
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Hospital Acquired Infections (HAI) Diagnostics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Hospital Acquired Infections (HAI) Diagnostics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Hospital Acquired Infections (HAI) Diagnostics Market Size Forecast by Type
11.6.1 Molecular Diagnostics Tests
11.6.2 Other In-vitro Diagnostic Tests
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Hospital Acquired Infections (HAI) Diagnostics Market Size Forecast by Applications
11.10.1 Bloodstream Infections (BSI)
11.10.2 Urinary Tract Infections (UTI)
11.10.3 Surgical Site Infections (SSI)
11.10.4 Pneumonia
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Hospital Acquired Infections (HAI) Diagnostics Analysis and Forecast
12.1 Introduction
12.2 Latin America Hospital Acquired Infections (HAI) Diagnostics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Hospital Acquired Infections (HAI) Diagnostics Market Size Forecast by Type
12.6.1 Molecular Diagnostics Tests
12.6.2 Other In-vitro Diagnostic Tests
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Hospital Acquired Infections (HAI) Diagnostics Market Size Forecast by Applications
12.10.1 Bloodstream Infections (BSI)
12.10.2 Urinary Tract Infections (UTI)
12.10.3 Surgical Site Infections (SSI)
12.10.4 Pneumonia
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Hospital Acquired Infections (HAI) Diagnostics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Hospital Acquired Infections (HAI) Diagnostics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Hospital Acquired Infections (HAI) Diagnostics Market Size Forecast by Type
13.6.1 Molecular Diagnostics Tests
13.6.2 Other In-vitro Diagnostic Tests
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Hospital Acquired Infections (HAI) Diagnostics Market Size Forecast by Applications
13.10.1 Bloodstream Infections (BSI)
13.10.2 Urinary Tract Infections (UTI)
13.10.3 Surgical Site Infections (SSI)
13.10.4 Pneumonia
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hospital Acquired Infections (HAI) Diagnostics Market: Competitive Dashboard
14.2 Global Hospital Acquired Infections (HAI) Diagnostics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 BioMérieux
14.3.2 Abbott Laboratories
14.3.3 Roche AG
14.3.4 Siemens Healthcare
